The calcium permeability of the mouse muscle nicotinic ACh receptor (nAChR) was determined using patch-clamp techniques. Single-channel currents were measured in pure external calcium and in mixtures of calcium with cesium or sodium. At low concentrations, calcium decreases the current carried by the monovalent cation. At higher concentrations, calcium displaces the monovalent cation as the main current carrier. In pure external calcium, the conductance of the nAChR is similar to the conductance of the NMDA receptor or the L-type Ca channel. With pure 110-mM calcium as the external cation, the slope conductance of the nAChR channel at negative potentials is 12 pS. An ion-permeation model based on the structure and function of the channel describes the currents. The ion-permeation model predicts that calcium contributes about 2% of the total inward current through a nAChR channel in physiologic solution. The current is about 7% of the calcium current through an L-type Ca channel. Because nAChRs are densely packed at the neuromuscular end plate, the calcium influx at an active synapse is expected to produce a locally high-calcium environment.

Sitaxsentan (1) (Wu et al. J. Med. Chem. 1997, 40, 1690) is our first endothelin antagonist being evaluated in clinical trials. It has demonstrated biological effects in an acute hemodynamic study in CHF (Givertz et al. Circulation 2000, 101, 2922), an open-label 20-patient pulmonary hypertension trial (Barst et al. Chest 2002, 121, 1860-1868), and a 31-patient trial in essential hypertension (Calhoun et al. AHA Scientific Sessions 2000). In a phase 2b/3 pulmonary arterial hypertension trial, once a day treatment of 100 mg of sitaxsentan statistically significantly improved 6-min walk distance and NYHA class at 12 weeks (Barst et al. Am. J. Respir. Crit. Care Med. 2004, 169, 441). We have since reported on our efforts in generating follow-up compounds (Wu et al. J. Med. Chem. 1999, 42, 4485) and recently communicated that an ortho acyl group on the anilino ring enhanced oral absorption in this category of compounds (Wu et al. J. Med. Chem. 2001, 44, 1211). Here we report an expansion of this work by substituting a variety of electron-withdrawing groups at the ortho position and evaluating their effects on oral bioavailability as well as structure-activity relationships. As a result, TBC3711 (7z) was identified as our second endothelin antagonist to enter the clinic due to its good oral bioavailability (approximately 100%) in rats, high potency (ET(A) IC(50) = 0.08 nM), and optimal ET(A)/ET(B) selectivity (441 000-fold). Compound 7z has completed phase-I clinical development and was well tolerated with desirable pharmacokinetics in humans (t(1/2) = 6-7 h, oral availability > 80%).

The addition of 2 M formic acid at pH 3.75 increased the single channel H+ ion conductance of gramicidin channels 12-fold at 200 mV. Other weak acids (acetic, lactic, oxalic) produce a similar, but smaller increase. Formic acid (and other weak acids) also blocks the K+ conductance at pH 3.75, but not at pH 6.0 when the anion form predominates. This increased H+ conductance and K+ block can be explained by formic acid (HF) binding to the mouth of the gramicidin channel (Km = 1 M) and providing a source of H+ ions. A kinetic model is derived, based on the equilibrium binding of formic acid to the channel mouth, that quantitatively predicts the conductance for different mixtures of H+, K+, and formic acid. The binding of the neutral formic acid to the mouth of the gramicidin channel is directly supported by the observation that a neutral molecule with a similar structure, formamide (and malonamide and acrylamide), blocks the K+ conductance at pH 6.0. The H+ conductance in the presence of formic acid provides a lower bound for the intrinsic conductance of the gramicidin channel when there is no diffusion limitation at the channel mouth. The 12-fold increase in conductance produced by formic acid suggests that greater than 90% of the total resistance to H+ results from diffusion limitation in the bulk solution.

The pulmonary vasculature of newborns with persistent pulmonary hypertension is characterized by active vasoconstriction and vascular remodeling. It has been suggested that endothelin-1 (ET-1), a potent vasoconstrictor and growth promoter, may be involved in the pathogenesis of persistent pulmonary hypertension of the newborn. To determine whether treatment with an ET A receptor antagonist can reverse pulmonary hypertension in the neonate, 1-d-old piglets were exposed to hypoxia for 3 d to induce pulmonary hypertension and then treated for the remainder of the 14 d with an orally active, nonpeptidic ET A antagonist (TBC3711, 22 mg·kg). At the end of the exposure, Hb, pulmonary artery pressure, right ventricle to left ventricle plus septum weight ratio, percentage wall thickness, ET-1 circulating levels, perfusion pressure, and dilator response to the nitric oxide (NO) donor, SIN-1 (3-morpholinosydnonimine-N-ethylcarbamide) in isolated perfused lungs were determined. Exhaled NO and hemodynamic variables were also examined in an intact anesthetized animal preparation that had undergone the same treatment. By 3 d of exposure to hypoxia, piglets had already developed significant pulmonary hypertension as estimated by their pulmonary artery pressure (24.0 Ϯ 1.3 mm Hg versus 14.2 Ϯ 3.4 mm Hg) and percentage wall thickness (26.6 Ϯ 5.9% versus 18.7 Ϯ 2.4% for vessels 0-30 m). Whereas further exposure to hypoxia for 14 d did not enhance the increase in pulmonary artery pressure and percentage wall thickness, it did augment the right ventricle to left ventricle plus septum weight ratio (0.71 Ϯ 0.09 versus 0.35 Ϯ 0.01). ET-1 circulating levels were increased only when exposure to hypoxia was prolonged to 14 d (5.1 Ϯ 2.4 pg/mL versus 1.0 Ϯ 0.4 pg/mL). Treatment with TBC3711 from d 3 to d 14, once pulmonary hypertensive changes were established and while hypoxic exposure persisted, caused significant reduction in the right ventricle to left ventricle plus septum weight ratio (0.60 Ϯ 0.06), pulmonary artery pressure (20.0 Ϯ 4.8 mm Hg), and percentage wall thickness (18.5 Ϯ 3.3%) and restored the dilator response to the NO donor SIN-1. Prolonged hypoxia markedly reduced exhaled NO concentrations (0.3 Ϯ 0.6 ppb), although treatment of hypoxic animals with TBC3711 restored the concentration of exhaled NO (4.4 Ϯ 2.8 ppb) to the level of normoxic controls (4.9 Ϯ 3.0 ppb). Lastly, treatment with TBC3711 increased ET-1 circulating levels in both the normoxic (5.4 Ϯ 2.8 pg/mL) and hypoxic (13.0 Ϯ 6.3 pg/mL) groups. In conclusion, the specific ET A receptor antagonist, TBC3711, can significantly ameliorate the morphologic changes encountered in hypoxia-induced pulmonary hypertension in the newborn piglet and may improve the dilator response to NO.

The results of Decker and Levitt (1987) suggest that the conductance of H+ ion through the gramicidin channel is limited primarily by diffusion in the bulk solution at the channel mouth. It is assumed in this paper that the H+ conductance is 100% diffusion limited. This means that all the factors that influence the H+ flux are external to the channel and are presumed to be known. In particular, the diffusion coefficient of H+ in this region is assumed to be equal to the bulk solution value and the only force acting on the ion is that due to the applied voltage. A model of the H+ flux is derived, based on the Nernst-Planck equation. It has three adjustable parameters: the electrostatic radius, the capture distance, and the radius of the H+ ion. The acceptable range of the parameters was determined by comparing the predictions of the model with the experimental measurements of the H+ conductance at pH 3.75. The best fit was obtained for an electrostatic radius in the range 2.3-2.7 A. This is in good agreement with earlier predictions (2.5 A) based on the assumption that the dielectric constant of the channel water is equal to that of bulk water. The addition of 1 M choline Cl- (an impermeant) increases the H+ current at low voltage and decreases it at high voltage. The increase can be explained by the small surface charge that results from the separation of charge produced by exclusion of the large choline cation (relative to Cl-) from the membrane surface. The decrease at high voltages can be accounted for by the change in the profile of the applied potential produced by the increase in ionic strength.